Glaxo Loses Paxil Suit At Federal Circuit
The court ruled in an “en banc” hearing that Apotex’ generic version would infringe one claim of Glaxo’s patent for the drug, but determined that the patent was invalid due to “inherent anticipation.”
The decision overturns an earlier determination by a panel of the U.S. Court of Appeals for the...
Already a subscriber? Click here to login